Michael D Schaffer

US Patent:

20040053230, Mar 18, 2004

Filed:

Aug 15, 2002

Appl. No.:

10/204889

Inventors:

Michael Schaffer - Boothwyn PA, US
Susan Tseng - Hockessin DE, US

International Classification:

C12Q001/68
G06F019/00
G01N033/48
G01N033/50

US Classification:

435/006000, 702/020000

Abstract:

The PCR-based, dsDNA quantification method monitors the fluorescence of a target, whose melting characteristics is predetermined, during each amplification cycle at selected time-points. Fluorescence is measured immediately after the annealing phase (Fat T), immediately below (Fat T) and above (Fat T) the melting of the target/amplicon. A change in slope from a baseline slope (S=-(F-F)/(T-T)) to a melting phase slope (S=-(F-F)/(T-T) indicates a specific amplification. The number of amplification cycles (C) it takes for the quantity (S-S) to become greater than zero correlates with the starting concentration of the target (C). The concentration of the target in a sample is determined by comparing the value of Cfor the sample with a standard curve. By selecting targets with distinguishable melting curve characteristics, multiple targets can be simultaneously detected.

US Patent:

20040175752, Sep 9, 2004

Filed:

Apr 21, 2004

Appl. No.:

10/829430

Inventors:

Michael Schaffer - Boothwyn PA, US
Susan Tseng - Hockessin DE, US

International Classification:

C12Q001/68
G06F019/00
G01N033/48
G01N033/50
C12P019/34

US Classification:

435/006000, 702/020000, 435/091200

Abstract:

The PCR-based, dsDNA quantification method monitors the fluorescence of a target, whose melting characteristics is predetermined, during each amplification cycle at selected time-points. Fluorescence is measured immediately after the annealing phase (Fat T), immediately below (Fat T) and above (Fat T) the melting of the target/amplicon. A change in slope from a baseline slope (S=-(F-F)/(T-T)) to a melting phase slope (S=-(F-F)/(T-T) indicates a specific amplification. The number of amplification cycles (C) it takes for the quantity (S-S) to become greater than zero correlates with the starting concentration of the target (C). The concentration of the target in a sample is determined by comparing the value of Cfor the sample with a standard curve. By selecting targets with distinguishable melting curve characteristics, multiple targets can be simultaneously detected.

US Patent:

63033844, Oct 16, 2001

Filed:

Mar 3, 2000

Appl. No.:

9/517891

Inventors:

Susan P. Mills - Ambler PA
John A. Novinski - Leesburg FL
Michael I. Schaffer - Woodland Hills CA

Assignee:

Quest Diagnostics Investments, Inc. - San Juan Capistrano CA

International Classification:

G01N 3348

US Classification:

436111

Abstract:

This invention relates to a reagent and use of that reagent for detecting adulterants in aqueous samples, particularly in biological specimens such as urine samples using a diazo dye precursor such as N,N diethyl-1,4-phenylene diamine and a reagent such as creatinine to stabilize a colored intermediate formed by the reaction of the diamine with nitrite ions for a period sufficient to allow that color to be recorded and compared with a separate peak formed by a halogen-based oxidizing agent which may be present in solution.

US Patent:

20160304962, Oct 20, 2016

Filed:

Mar 11, 2016

Appl. No.:

15/067716

Inventors:

- BEERSE, BE
Shibu Thomas - North Wales PA, US
Michael Gormley - Mount Laurel NJ, US
Yashoda Rajpurohit - Hillsborough NJ, US
Michael Schaffer - Fort Washington PA, US

International Classification:

C12Q 1/68

Abstract:

Provided are whole blood based mRNA biomarkers for predicting prostate cancer and methods of detecting the same. The disclosed mRNA markers and methods enable the identification/diagnosis of a patient with prostate cancer, identification of a patient with/prediction of high-risk prostate cancer, and treatment of a patient with prostate cancer. Also provided are gene chips comprising the disclosed whole blood based mRNA biomarkers.

US Patent:

20150322523, Nov 12, 2015

Filed:

May 12, 2015

Appl. No.:

14/710093

Inventors:

- Beerse, BE
Weimin Li - Norristown PA, US
Michael Gormley - Mount Laurel NJ, US
Jayaprakash Karkera - Germantown MD, US
Michael Schaffer - Fort Washington MD, US

International Classification:

C12Q 1/68
A61K 31/573
A61K 31/58

Abstract:

Provided herein are methods of predicting a likelihood of survival following treatment with AA and prednisone in a patient having CRPC.